Navigation Links
Canada-wide study on slow progressors to investigate new treatments for HIV

This press release is available in French.

Montreal, Febrauary 6, 2009 -- Why do some HIV patients manage to control the progression of their infection naturally over long periods of time? As part of a nation-wide investigation, a team of researchers will examine that question and others as they work to develop new strategies to fight AIDS.

The five-year study will be headed by Dr. Ccile Tremblay, a physician and investigator with the Centre hospitalier de l'Universit de Montral's Research Centre (CRCHUM) and a professor at the Universit de Montral, thanks to nearly $1 million in support from the Canadian Institutes for Health research (CIHR).

In light of a limited success in developing vaccine therapies, it has become clear that the scientific community needs to place greater emphasis on the basic research necessary to address the many unanswered questions that remain about HIV. One of the best approaches to try to develop effective vaccines is the study of HIV-infected individuals who control their infection naturally and do not show disease progression over a long period of time. Called slow progressors (SP), these individuals make up less than 1percent of HIV-infected population. Some of the questions that this study will address include:

  • What constitutes a protective immune response?
  • What are the drivers of HIV diversity?
  • Can we develop broadly neutralizing antibodies?
  • And, ultimately, how can this understanding lead to the development of an effective vaccine?

Conducting a study of this nature requires a sufficiently large pool of slow progessors. Enter Dr. Tremblay, whose team has assembled a unique cohort of slow progessors in Quebec and, thanks to the CIHR funding, she will expand it throughout Canada. This national effort will involve the collaboration of major HIV clinical scientists across the country, including in Toronto, Vancouver and Victoria, as well as international colleagues.

The cohort will enable researchers to gather important information concerning the clinical course of HIV, which may lead to the identification of factors that predict a favourable outcome. The study will enable the collection of samples that will be stored in a specimen bank, which will be made available to various investigators investigating the progression of HIV.

The project aims to determine the natural history of the disease over a five-year period. It will also focus on the impact of viral genetic evolution on the immune system through the collection of clinical, demographic, social and behavioural data that will be analyzed in correlation with virological, immunological and genetic findings.


Contact: Nathalie Forgue
University of Montreal

Related medicine news :

1. New Vivisimo Case Study Details Medical Search
2. Penn study shows how electronic medical records can be used to test drug efficacy
3. Genome Study Points to New Culprit for Schizophrenia
4. New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia
5. New Study Provides Benchmarks for Best Practices for Valuing Internal Consulting Organizations
6. MSU study finds high level of medical mistrust among minority women impacts quality of health care
7. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
8. New study raises concerns about screen time among urban children with asthma
9. Study Reveals Consumers Want to Buy Products That Dental Hygienists Recommend
10. Methamphetamine use cost the US about $23 billion in 2005, RAND study estimates
11. USC study finds that green tea blocks benefits of cancer drug
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... SPH ... has been named the organization’s Executive Vice President of Operations, and three Senior ... key leadership roles in the company. , Debbie Vereb’s appointment to Executive Vice ...
(Date:10/13/2015)... Richmond, Virginia (PRWEB) , ... ... ... American International Biotechnology, LLC presented results from GyencoloGeneTM, the world’s first commercially-available ... at the XXI FIGO World Congress of Gynecology and Obstetrics in Vancouver, ...
(Date:10/12/2015)... Provo, Utah (PRWEB) , ... October 13, 2015 ... ... and corporate training, is proud to announce the release of its new Professional ... course prepares students to use both the ICD-10-CM and ICD-10-PCS code sets, earn ...
(Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... ... on August 19, 2015, high school aged female athletes, particularly in the ... potentially sidelining repetitive motion and mechanical overuse injuries than male peers in the ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an article ... of San Antonio, Texas recommended that any high-rises in the city limits that do ... going forward. The article explains that it wasn’t until 1982 that the city started ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Okla. , Oct. 12, 2015  Millions of ... free from the shackles of tobacco. An April ... at Kings College London showed electronic cigarettes to be ... smoking. But more than a decade after the technology ... it remained unchanged.    --> ...
(Date:10/12/2015)... , Oct. 12, 2015 ... improve and enhance the quality of images produced ... substances (contrast media) used in magnetic resonance imaging, ... These devices allow the radiologists to interpret the ... conditions of the body. Contrast media can be ...
(Date:10/12/2015)... -- In a Sutter Institute of Medical Research study published ... Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was ... patients in the early, pre-dementia phase of Alzheimer,s disease. ... extracted from the plasma of more than 1,000 blood ... found in patients with Alzheimer,s disease. Sutter Institute of ...
Breaking Medicine Technology: